FDA Biologics/Biosimilars Staff Director Leah Christl Leaves For Amgen

FDA’s Leah Christl, head of the agency’s biologics and biosimilars staff in the Office of New Drugs (OND), will leave FDA on Feb. 22, after 16 years of working with the agency, drug center director Janet Woodcock announced in an email to center staff on Friday (Feb. 1). Sarah Yim, the agency announced, will replace Christl as acting director. Christl will join Amgen as executive director of its Global Regulatory and R&D Policy group, Amgen confirmed to Inside Health Policy...